Brainvivo

Brainvivo operates at the intersection of neurotechnology, machine learning, neuroscience, digital health, and cognitive computing. Its stated differentiation is not simply the use of AI for healthcare data; it is the attempt to construct individualized computational models from MRI scans and real-world content. The BrainTwin concept aims to encode neural responses, perceptions, emotions, and cognitive processes, while the company’s content-to-brain encoder, generative content-to-brain model, and brain-to-cognitive-process decoder suggest a vertically integrated approach spanning biological measurement, modeling, and application delivery. Brain Collection and Brain Applications extend that proposition from one person’s model toward reusable expert knowledge and developer-facing software. The company also emphasizes participant autonomy, transparency, and joint ownership of personal BrainTwins, which could become a meaningful differentiator in a sensitive data category. Brainvivo is smaller than established AI and neurotechnology platforms, with an employee range of 1–10 and three disclosed funding rounds. Its four granted patents and two registered trademarks provide some evidence of proprietary development, but commercial scale, customer adoption, and revenue remain undisclosed.

Brainvivo’s trajectory shows a progression from foundational research toward products and application infrastructure. The company was founded on Jun 1, 2016 by Assaf Horowitz and Yaniv Assaf, followed by a Pre-Seed round dated Oct 1, 2017 and a Seed round dated Oct 1, 2019. A Series A on Jun 26, 2022, with Corner Ventures identified as an investor, marks the clearest financing inflection point. The company now presents a multi-layer product model: BrainTwin for individualized neural representations, Brain Collection for aggregating digitized expert knowledge, Brain Applications for developer use, and Brainvivo Open Brain for open experimentation. Its intellectual-property activity also expanded, including the Apr 23, 2023 publication associated with “Segmenting audiences using brain type information.” Team development is visible in Sharon Rousso’s Head of Product role from January 2020 and Stav Avrahami’s business role from May 2022, alongside continued leadership by the two founders. However, the available profile does not disclose funding amounts, revenue, customer counts, product-launch dates, or employee-growth figures. Active recruiting suggests ongoing development, but the absence of post-2022 financing and operating metrics limits confidence in the company’s current commercial momentum.